熱門資訊> 正文

展望Therapeutics 2026年第三季度盈利预览

2026-08-14 02:43

Outlook Therapeutics (OTLK) is scheduled to announce Q3 earnings results on Friday, August 14th, before market open.
The consensus EPS Estimate is -$0.07 (+84.1% Y/Y) and the consensus Revenue Estimate is $0.97M (-35.8% Y/Y).
Over the last 1 year, OTLK has beaten EPS estimates 50% of the time and has beaten revenue estimates 0% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 2 downward.

More on Outlook Therapeutics

Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs
Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity
Outlook Therapeutics slides after pricing $55M securities offering
Outlook gains as wet AMD therapy reconsidered for FDA review

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。